Emerging IO checkpoints in gastrointestinal oncology
Recent progress in immunotherapy has significantly altered the therapeutic approach for gastrointestinal cancers, which are historically challenging due to their intricate pathologies and unfavorable outcomes. This review emphasizes the growing importance of immune checkpoints like TIGIT, VISTA, GIT...
Saved in:
| Main Authors: | Alireza Tojjari, Anwaar Saeed, Ludimila Cavalcante |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1575713/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?
by: Haozhe Cui, et al.
Published: (2024-11-01) -
Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor
by: Jingjing Zhao, et al.
Published: (2023-12-01) -
Exploring IgSF11 as a potential immune checkpoint and immunotherapeutic target in breast cancer
by: Ibtissam Rezouki, et al.
Published: (2025-08-01) -
New horizons in B-cell lymphoma immunotherapy: From immune checkpoints to precision medicine
by: RuiXin Zheng, et al.
Published: (2025-09-01) -
Tiragolumab and TIGIT: pioneering the next era of cancer immunotherapy
by: Kosar Ghasemi, et al.
Published: (2025-06-01)